Rapid Therapeutic Science Laboratories (RTSL) 10-K 16 Mar 22 2021 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 16, 2022	Jun. 30, 2021
Details
Registrant CIK	0001575659
Fiscal Year End	--12-31
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Document Transition Report	false
Entity File Number	000-55018
Entity Registrant Name	Rapid Therapeutic Science Laboratories, Inc.
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	46-2111820
Entity Address, Address Line One	5580 Peterson Lane, Suite 120
Entity Address, City or Town	Dallas
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75201
City Area Code	800
Local Phone Number	497-6059
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 50,343,000
Entity Common Stock, Shares Outstanding		193,666,921
Auditor Firm ID	6686
Auditor Name	PWR CPA, LLP
Auditor Location	Texas
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 192,484	$ 499,146
Inventory, net	175,047	186,802
Prepaid expenses	51,631	0
Total current assets	419,162	685,948
Property and equipment:
Property and equipment, gross	1,214,917	606,740
Accumulated depreciation	(29,355)	(7,255)
Net property and equipment	1,185,562	599,485
Other long-term assets
Operating lease right-of-use asset, net	425,171	0
Sublicense agreement, net	170,075	227,500
Total assets	2,199,970	1,512,933
Current liabilities
Accounts payableand accrued liabilities, net	465,204	112,298
Notes payable - related party	283,700	23,700
Convertible notes payable - other	1,099,734	674,927
Accrued interest payable	45,696	354,659
Current portion of operating lease obligation	73,289	0
Warrant liability and other derivatives	1,085,360	43,306
Total current liabilities	3,052,983	1,208,890
Long-term liabilities
Convertible notes payable	150,000	315,240
Long-term portion of operating lease obligation	378,744	0
Total liabilities	3,581,727	1,524,130
Stockholders' deficit
Preferred stock value	0	0
Common stock value	193,567	180,937
Additional paid in capital	7,283,438	5,798,745
Accumulated deficit	(8,521,423)	(5,653,540)
Treasury stock	(337,339)	(337,339)
Total stockholders' deficit	(1,381,757)	(11,197)
Total liabilities and stockholders' deficit	$ 2,199,970	$ 1,512,933

Consolidated Balance Sheets - P

Consolidated Balance Sheets - Parenthetical - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Accumulated amortization, Sublicense Agreement	$ 0	$ 112,500
Preferred Stock, Par or Stated Value Per Share	$ 0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	750,000,000	750,000,000
Common Stock, Shares, Outstanding	193,566,921	180,936,608
Series A Preferred Stock
Preferred Stock, Shares Authorized	16,500,000
Series B Preferred Stock
Preferred Stock, Shares Authorized	2,000,000
Series C Preferred Stock
Preferred Stock, Shares Authorized	8,500,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Details
Revenues	$ 534	$ 130,916
Cost of goods sold	200	19,394
Gross profit	334	111,522
Operating expenses
General and administrative	2,114,770	2,023,379
Amortization expense	33,759	75,000
Depreciation expense	22,100	7,255
Total operating expenses	2,170,629	2,105,634
Other income (expense)
Gain (loss) on valuation of warrant liability	631,853	0
Interest expense	(1,329,441)	(58,009)
Total other income (expense)	(697,588)	(58,009)
Net loss before income taxes	(2,867,883)	(2,052,121)
Income taxes	0	0
Net (loss)	$ (2,867,883)	$ (2,052,121)
Net loss per share, basic and diluted	$ (0.02)	$ (0.01)
Weighted average shares outstanding, basic and diluted	190,739,289	168,759,123

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Common Stock	Additional Paid-in Capital	Retained Earnings	Treasury Stock	Total
Equity Balance at Dec. 31, 2019	$ 159,556	$ 2,414,718	$ (3,601,419)	$ (337,339)	$ (1,364,484)
Equity Balance, Shares at Dec. 31, 2019	159,556,000
Stock issued for conversion of debt, value	$ 10,104	524,970	0	0	535,074
Stock issued for conversion of debt, shares	10,103,524
Stock issued for aquisition of assets, value	$ 625	499,375	0	0	500,000
Stock issued for aquisition of assets, shares	625,000
Private offering of common stock, value	$ 9,289	2,003,211	0	0	2,012,500
Private offering of common stock, shares	9,288,750
Share-based compensation, value	$ 1,363	356,471	0	0	357,834
Share-based compensation, shares issued	1,363,334
Net (loss)	$ 0	0	(2,052,121)	0	(2,052,121)
Equity Balance at Dec. 31, 2020	$ 180,937	5,798,745	(5,653,540)	(337,339)	(11,197)
Equity Balance, Shares at Dec. 31, 2020	180,936,608
Stock issued for conversion of debt, value	$ 11,094	878,937	0	0	890,031
Stock issued for conversion of debt, shares	11,094,585
Stock issued for aquisition of assets, value					0
Private offering of common stock, value	$ 1,463	583,537	0	0	585,000
Private offering of common stock, shares	1,462,500
Share-based compensation, value	$ 50	19,950	0	0	20,000
Share-based compensation, shares issued	50,000
Net (loss)	$ 0	0	(2,867,883)	0	(2,867,883)
Equity Balance at Dec. 31, 2021	$ 193,567	7,283,438	(8,521,423)	(337,339)	(1,381,757)
Equity Balance, Shares at Dec. 31, 2021	193,566,921
Stock issued for accrued interest and lending fees, value	$ 23	$ 2,269	$ 0	$ 0	$ 2,292
Stock issued for accrued interest and lending fees, shares	23,228

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net (loss)	$ (2,867,883)	$ (2,052,121)
Adjustments to reconcile net loss to net cash provided by (used in) operations
Gain (loss) on valuation of warrant liability	(631,853)	0
Amortization of debt discount	1,147,865	0
Stock-based compensation expense	20,000	357,834
Amortization of sublicense fees	12,500	75,000
Amortization of operating lease asset	21,259	0
Depreciation expense	22,100	7,255
Changes in operating assets and liabilities
Increase (decrease) in inventory	11,755	(180,929)
Increase (decrease) in prepaid expenses	(51,631)	0
Increase (decrease) in accounts payable and accrued liabilities	82,185	47,721
Increase (decrease) in Accrued interest payable	24,572	52,411
Increase (decrease) in contract liabilities	0	(32,000)
Net cash flows used in operating activities	(2,209,131)	(1,724,829)
Cash flows from investing activities
Additions to property and equipment	(292,531)	(106,740)
Net cash flows used in investing activities	(292,531)	(106,740)
Cash flows from financing activities
Private offering of common stock	585,000	2,012,500
Proceeds from Issuance of convertible debenture payable	1,650,000	0
Proceeds from notes payable - related party	260,000	0
Proceeds from notes payable - other	0	422,000
Payments of notes payable - other	(300,000)	(150,000)
Equity subscription payable	0	(90,000)
Net cash flows provided by financing activities	2,195,000	2,194,500
Net increase (decrease) in cash and cash equivalents	(306,662)	362,931
Cash and cash equivalents at beginning of period	499,146	136,215
Cash and cash equivalents at end of period	192,484	499,146
Supplemental cash flow data
Cash paid for interest	0	5,599
Cash paid for income taxes	0	0
Non-Cash financing activities
Stock issued for aquisition of assets, value	0	500,000
Accounts payable for acquisition of equipment	315,646	0
Operating lease obligation for acquisition of right-of-use asset	446,429	0
Convertible notes and interest converted to common stock	$ (892,323)	$ (535,074)

General Organization and Busine

General Organization and Business	12 Months Ended
	Dec. 31, 2021
Notes
General Organization and Business	(1) General Organization and Business The Company we our Company Impact of COVID-19 Pandemic on Consolidated Financial Statements COVID-19

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Notes
Summary of Significant Accounting Policies	(2) Summary of Significant Accounting Policies Basis of Accounting - Principles of Consolidation - Change in Fiscal Year - Cash and Cash Equivalents - Inventory - Property and Equipment Intangible Assets - Revenue recognition FASB ASU Revenue from Contracts with Customers (Topic 606). Earnings per Share - Income Taxes - Use of Estimates - Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from estimates. Fair Value of Financial Instruments - Level 1: The preferred inputs to valuation efforts are “ quoted prices in active markets for identical assets or liabilities, Level 2: FASB acknowledged that active markets for identical assets and liabilities are relatively uncommon and, even when they do exist, they may be too thin to provide reliable information. To deal with this shortage of direct data, the board provided a second level of inputs that can be applied in three situations. Level 3: If inputs from levels 1 and 2 are not available, FASB acknowledges that fair value measures of many assets and liabilities are less precise. The board describes Level 3 inputs as “ unobservable, Recently Issued Accounting Pronouncements Subsequent Events

Going Concern Disclosure

Going Concern Disclosure	12 Months Ended
	Dec. 31, 2021
Notes
Going Concern Disclosure	(3) Going Concern The Company's consolidated financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has generated minimal revenues and has suffered recurring losses totaling $8,521,423 since inception. These factors, among others, indicate that there is substantial doubt about the Company’s ability to continue as a going concern within one year from the issuance date of this filing. In order to obtain the necessary capital to sustain operations, management’s plans include, among other things, the possibility of pursuing new equity sales and/or making additional debt borrowings. There can be no assurances, however, that the Company will be successful in obtaining such additional financing, or that such financing will be available on favorable terms, if at all. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from the outcome of this uncertainty.

Intangible Assets Disclosure

Intangible Assets Disclosure	12 Months Ended
	Dec. 31, 2021
Notes
Intangible Assets Disclosure	(4) Intangible Assets The Company has acquired certain intangible asset rights to use the metered dose inhaler (MDI) developed by EM3 Methodologies, LLC (“ EM3 EM3 Exclusive License Effective November 15, 2019, we entered into a sublicense agreement (the “ TMDI Agreement TMDI TM Original EM3 Exclusive License Effective February 9, 2021, both the TMDI Agreement and the Original EM3 Exclusive License were effectively terminated by mutual agreement of all parties and EM3 agreed to provide the Company with a royalty-free, perpetual license to use the Desirick Procedure or any derivation thereof and its application and use on an exclusive basis in the states of Texas, California, Florida and Nevada (subject to pre-existing licensing rights which have been provided by EM3 in such jurisdictions), and on a non-exclusive basis throughout the rest of the world. During the term of the TMDI Agreement, we were required to reimburse TMDI for the initial two year license fee owed by TMDI to EM3 in the amount of $200,000. We partially satisfied this obligation by making an equipment purchase on behalf of EM3 in the amount of $135,000, and agreed to pay the remaining license fee of $65,000, either by making cash fee payments or by making cash purchases of certain supplies from EM3, within a 24-month period (for which, we had recorded a liability of $44,925 for the unpaid portion of this amount in accounts payable as of December 31, 2020). We had recorded the entire $200,000 license fee as an intangible asset and were amortizing such expense on a straight-line basis over a 24-month period at the rate of $25,000 per quarter. Pursuant to the termination of the two agreements on February 9, 2021, we no longer owe TMDI (or EM3) any license fees under either agreement (including, the accrued liability of $44,925). Effective in February 2021, the Company is accounting for the licenses as an indefinite life asset not subject to amortization, resulting in the remaining balance of $170,075 being subjected to impairment testing at least annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired.

Asset Acquisition Disclosure

Asset Acquisition Disclosure	12 Months Ended
	Dec. 31, 2021
Notes
Asset Acquisition Disclosure	(5) Asset Acquisition On November 16, 2020, the Company closed an Asset Purchase and Sales Agreement with Razor Jacket, LLC (“ Razor Jacket RJ Agreement The Company has accounted for this transaction as an acquisition of assets, pursuant to the provisions of Accounting Standards Codification (ASC) 805-50. Accordingly, we have accounted for each component of the purchase price as follows: · · · Razor Jacket was originally formed in July 2019 for the sole purpose of researching techniques for the extraction of isolates from raw hemp. We have not presented any pro forma disclosures relating to this acquisition in the notes to our financial statements because the transaction is deemed an asset acquisition.

Property and Equipment Disclosu

Property and Equipment Disclosure	12 Months Ended
	Dec. 31, 2021
Notes
Property and Equipment Disclosure	(6) Property and Equipment As of December 31, 2021, and December 31, 2020, the Company had the following balances of property and equipment: December 31, 2021 2020 Equipment purchased from Razor Jacket, LLC and awaiting installation in the Company's new facilities in Addison, Texas $ 500,000 $ 500,000 Equipment located in the Company's existing facilities in Addison, Texas 221,412 104,240 Leasehold improvements in progress at the Company's new facilities in Addison, Texas 491,005 - Leasehold improvements in the Company's existing facilities in Addison, Texas 2,500 2,500 Total property and equipment 1,214,917 606,740 Less: Accumulated depreciation (29,355) (7,255) Net property and equipment $ 1,185,562 $ 599,485 Effective October 1, 2021, the Company entered into a lease agreement with a landlord to lease 8,566 square feet of commercial office building space located in Addison, Texas (see Note 8). As of December 31, 2021, the Company was in the process of building out this space with the intention of utilizing it as its corporate office as well as its aerosol filling laboratory and isolate manufacturing facility, beginning in the first or second quarter of 2022. As of December 31, 2021, the Company had capitalized leasehold improvements in progress at the new location in the amount of $491,005, of which $315,646 had not been paid and is reflected in Accounts Payable as of that date. The equipment purchased from Razor Jacket, LLC in November 2020 was recently shipped to the Company’s existing facilities near Dallas, Texas, where it is awaiting installation in the new location in Addison, Texas, referenced above (see Note 5).

Notes Payable Disclosure

Notes Payable Disclosure	12 Months Ended
	Dec. 31, 2021
Notes
Notes Payable Disclosure	(7) Notes Payable As of December 31, 2021 and 2020, the Company had the following note payable obligations: December 31, 2021 2020 Convertible debenture issued to an accredited investor on August 4, 2021, due May 1, 2022 in principal amount of $1,941,176, original issue discount of 15%, convertible at option of investor into a total of 4,852,940 shares of common stock at $0.40 per share and automatically convertible at 25% discount to the price per share of common stock in a qualified offering (net of unamortized debt discount of $866,128 as of December 31, 2021) $ 1,075,048 $ - Promissory note issued to an accredited investor on November 10, 2020, accruing interest at 5% per annum, due on January 10, 2021, along with lending fee of 20,000 shares of common stock - 300,000 Convertible promissory notes issued to two accredited investors on November 15, 2019, maturing in 1 to 5 years, accruing interest at 5% per annum, convertible into common stock at $0.05 per share 150,000 150,000 Unsecured advances received from two officers in May through August 2021, accruing interest at 1% per annum, payable on demand 260,000 - - Convertible promissory notes issued to former owners in acquisition of Power Blockchain, accruing interest at 5% per annum, principal repayments originally due in four equal installments on 2nd, 3rd, 4th and 5th anniversaries, convertible into common stock at $0.13 per share, with final maturity on February 1, 2023. - 165,240 Other short term notes issued to various affiliates of the former owners of Power Blockchain for acquisition of Treasury Stock, computers and equipment, and working capital financing, at stated interest rates of 10%. Amended on November 15, 2019, to mature in one year and to be convertible into common stock at $0.05 per share. 48,386 351,933 Convertible notes issued to an accredited investor in three tranches from June to August 2020, net of unamortized debt discount of $43,306 (see further discussion below) - 46,694 Total notes payable $ 1,533,434 $ 1,013,867 Future maturities of notes payable as of December 31, 2021, without taking into account the unamortized debt discount, are as follows: Year ending December 31, 2022 $ 2,249,562 Year ending December 31, 2023 - Year ending December 31, 2024 150,000 $ 2,399,562 On August 4, 2021, the Company closed a short-term bridge loan with an institutional investor in the gross amount of $1,941,176. The closing of this bridge loan resulted in net proceeds to the Company of $1,650,000, after deducting the 15% original issue discount, which the Company is accreting as a non-cash charge to interest expense over the term of the loan. We recorded amortization on this original issue discount for the period from August 4, 2021 to December 31, 2021, in the amount of $161,764. The bridge loan is in the form of a convertible debenture with a maturity date of May 1, 2022 or earlier upon the closing of a public offering of common stock and/or common stock equivalents which results in the listing of the Company’s common stock on a national securities exchange (including Nasdaq). The debenture may not be prepaid without the prior written consent of the investor and does not accrue interest, except upon the occurrence of an event of default, at which time the amount owed accrues interest at the rate of 18% per annum, until paid in full. While the debenture is outstanding, the Company is prohibited from incurring additional indebtedness, repurchasing its securities or repaying certain of its indebtedness, paying cash dividends or other distributions on equity securities, other than pursuant to certain limited exceptions. The debenture is convertible into shares of the Company’s common stock at the lower of: (a) (b) The conversion of the debenture is subject to a beneficial ownership limitation of 4.99%, preventing such conversion by the holder thereof, if such exercise would result in such holder and its affiliates, exceeding ownership of 4.99% of our common stock, which percentage may be increased to up to 9.99%, with at least 61 days prior written notice by the holder thereof. The Company early adopted the provisions of ASU 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity In conjunction with the convertible debenture, we granted the investor five-year warrants to purchase a total of 4,852,940 shares of our common stock at an exercise price of $0.40 per share. Such warrants have cashless exercise rights if when exercised, and following the six-month anniversary of the closing of the offering, a registration statement for the underlying shares of common stock, is not effective. The exercise of the warrants is subject to a beneficial ownership limitation of 4.99%, preventing such exercise by the holder, if such exercise would result in such holder and its affiliates, exceeding ownership of 4.99% of our common stock, which percentage may be increased to up to 9.99% with at least 61 days prior written notice by the holder. The warrants contain anti-dilution rights such that if we issue, or are deemed to have issued, common stock at a price less than the then exercise price of the warrants, subject to certain exceptions, the exercise price of the warrants is automatically reduced to such lower value, and the number of shares of common stock issuable upon exercise thereafter is adjusted proportionately so that the aggregate exercise price payable upon exercise of such warrants is the same prior to and after such reduction in exercise price. The warrants also require the Company, at the holder’s option, following a Fundamental Transaction (as defined in the agreement), to purchase the warrants from the holder in cash, based on the Black Scholes value (as calculated pursuant to the terms of the warrant). Additionally, we made a grant to the placement agent for the bridge loan of warrants to purchase a total of 242,647 shares of our common stock at an exercise price of $0.40 per share, with substantially similar terms. All of these warrants are outstanding as of December 31, 2021. The Company accounted for the issuance of the warrants as a liability recorded at fair value in accordance with ASC 480-10. Using the Black Scholes model, the warrant liability was valued at issuance in the amount of $1,717,213. This was recorded as a discount to the convertible debt of $1,650,000 with the excess $67,213 expensed as interest. The Company accreted the debt discount to interest expense over the term of the convertible debenture. Debt discount amortization for the period from August 4, 2021 to December 31, 2021 totaled $980,497. As of December 31, 2021, we adjusted the warrant liability, to its then current fair value of $1,085,360, based on the Black Scholes model, resulting in a gain on warrant liability of $631,853 that was recorded in the statement of operations. Prior to obtaining the bridge loan noted above, the Company received unsecured cash advances from two of its officers from May through August 2021, in the net amount of $260,000. These related party advances accrue interest at the rate of 1% per annum and are payable on demand. Such advances are expected to be repaid out of the proceeds of an underwritten public offering of the Company’s equity securities in conjunction with the planned listing on a national exchange. However, no assurance can be given that the Company will be successful in achieving a closing of the underwritten public offering. Effective August 31, 2020, the Company reached the necessary milestone to trigger the conversion of certain notes payable issued on various dates in 2018 and 2019, as amended, in the total principal amount of $732,835, into shares of the Company’s common stock, at a conversion price of $0.05 per share, subject to a 4.99% ownership limitation for each beneficial owner of such notes. In conjunction with this conversion, holders of notes in the principal amount of $404,601, plus additional accrued interest in the amount of $96,536, converted their notes into 10,022,749 shares of common stock at that time. Effective March 31, 2021, the following additional conversions of the Company’s remaining convertible notes payable occurred: (i) the holders of convertible notes payable issued in 2018 at a conversion price of $0.13 per share, with total principal and accrued interest balances in the aggregate amount of $410,888, converted their notes into a total of 3,160,684 shares of common stock; and (ii) the holders of convertible notes payable amended or issued in 2019 at a conversion price of $0.05 per share, with total principal and accrued interest balances in the aggregate amount of $383,470, the automatic conversion of which had previously been triggered on August 31, 2020, as discussed above, subject to each holder’s beneficial ownership limitation, converted their notes into a total of 7,669,381 shares of common stock. As a result of these conversions, a total of 10,830,065 new shares of common stock were issued. As of December 31, 2021, convertible notes payable in the amount of $174,685, plus accrued interest in the amount of $38,683, remain outstanding and are available to be subsequently converted into 4,267,360 shares of common stock, subject to the ownership limitation (see Note 9). From June 30, 2020 to August 14, 2020, the Company entered into three identical Securities Purchase Agreements with an accredited investor (the “Buyer”) with respect to Convertible Promissory Notes (the “Notes”) issued by the Company to the Buyer in the total amount of $125,000. The Notes had a maturity date of one year after the date of each issuance and bore interest at a rate of 12% per annum, which was not due until maturity. At the option of the Buyer, the Notes could be converted into shares of the Company’s common stock, beginning one hundred eighty (180) days following the date of each issuance. Under this option, the conversion price was equal to a discount of 42% of the average of the three (3) lowest closing bid prices for the common stock during the prior fifteen (15) trading day period. The Buyer was limited to a 4.99% beneficial ownership limitation in connection with such conversion right under the note. The Company determined that the conversion feature of the Notes required the recognition of a derivative liability upon each issuance. Accordingly, the Company calculated the fair value of these derivative liabilities, using the Black Scholes model, and recognized a derivative liability for each Note in that amount offset by a debt discount. On December 30, 2020, the Buyer elected to exercise the conversion option on $35,000 of principal of the first Note resulting in the issuance of 80,775 shares of common stock to the Buyer. In the three months ended March 31, 2021, the Buyer elected to exercise the conversion option on the remaining principal of the first Note and the entire principal of the second and third Notes resulting in the issuance of 264,520 shares of common stock to the Buyer. Effective November 15, 2019, the following transactions took place in the Company’s notes payable: · · · The Company performed an analysis of both the newly issued convertible notes and the newly amended existing notes, which were formerly non-convertible, to determine whether there was a beneficial conversion feature and noted none.

Long Term Lease Obligation Disc

Long Term Lease Obligation Disclosure	12 Months Ended
	Dec. 31, 2021
Notes
Long Term Lease Obligation Disclosure	(8) Long Term Lease Obligation Effective October 1, 2021, the Company entered into a lease agreement with a landlord to lease 8,566 square feet of commercial office building space located in Addison, Texas (see Note 6). The lease agreement is for a total term of 63 months, beginning October 1, 2021 and ending December 31, 2026. As of December 31, 2021, the Company is building out this space and intends to utilize it as its corporate office as well as its aerosol filling laboratory and isolate manufacturing facility. The Company is accounting for the lease agreement as an operating lease under ASU 2016-02, Leases (Topic 842). Accordingly, the Company has capitalized the present value of the future lease obligations and is amortizing the related right-of-use asset on a straight-line basis each month over the term of the lease. Future operating lease minimum payments, together with their present values as of December 31, 2021, are summarized as follows: Year ending December 31, 2022 $ 94,226 Year ending December 31, 2023 98,509 Year ending December 31, 2024 102,792 Year ending December 31, 2025 107,075 Year ending December 31, 2026 111,358 Total future minimum lease payments 513,960 Less amounts representing interest (61,927) Present value of lease liability 452,033 Current portion of operating lease liability (73,289) Long-term portion of operating lease liability $ 378,744 As of December 31, 2021, the operating lease right-of-use asset and operating lease liabilities were $425,171 and $452,033, respectively. The long-term portion of the operating lease liabilities, $378,744, is included in long-term obligations. As of December 31, 2021, the weighted-average discount rate for this operating lease was 5%. The future operating lease payments are guaranteed by an employee of the Company.

Stockholders' Equity Disclosure

Stockholders' Equity Disclosure	12 Months Ended
	Dec. 31, 2021
Notes
Stockholders' Equity Disclosure	(9) Stockholders’ Equity Effective January 13, 2020, the Company filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Nevada to increase the total authorized shares of common stock of the Company from 200 million shares to 750 million shares and to authorize 100 million shares of “blank check” Preferred Stock of the Company. Subsequently, the Company filed three separate designations of preferred stock with the Secretary of State of Nevada, beginning in November 2020, designating 16,500,000 shares of Series A Preferred Stock, 2,000,000 shares of Series B Preferred Stock, and 8,500,000 shares of Series C Preferred Stock, however, no shares of preferred stock have been issued to date. Effective August 31, 2020, the Company reached the necessary milestone to trigger the conversion of certain notes payable issued to the holders on various dates in 2018 and 2019, as amended, in the total principal amount of $732,835 into shares of the Company’s common stock, at a conversion price of $0.05 per share, subject to a 4.99% ownership limitation for each beneficial owner of such notes. In conjunction with this conversion, holders of notes in the principal amount of $404,601, plus an additional accrued interest amount of $96,536, converted their notes into 10,022,749 shares of common stock at that time. Effective March 31, 2021, the following additional conversions of the Company’s remaining convertible notes payable occurred: (i) the holders of convertible notes payable issued in 2018 at a conversion price of $0.13 per share with total principal and accrued interest balances in the aggregate amount of $410,888 converted their notes into a total of 3,160,684 shares of common stock; and (ii) the holders of convertible notes payable amended or issued in 2019 at a conversion price of $0.05 per share with total principal and accrued interest balances in the aggregate amount of $383,470, the automatic conversion of which had previously been triggered on August 31, 2020, as discussed above, subject to each holder’s beneficial ownership limitation, converted their notes into a total of 7,669,381 shares of common stock. As a result of these conversions, a total of 10,830,065 new shares of common stock were issued. As of December 31, 2021, convertible notes payable in the amount of $174,685, plus accrued interest in the amount of $38,683, remain outstanding and are available to be subsequently converted into 4,267,360 shares of common stock, subject to the ownership limitation (see Note 7). During the year ended December 31, 2021, the Company entered into private stock subscription agreements with several accredited investors whereby it sold them a total of 1,462,500 shares of restricted common stock at an offering price of $0.40 per share, resulting in gross proceeds to the Company of $585,000. The investors also received an equal number of warrants to purchase additional shares of common stock at exercise prices of $0.85 to $1.00 per share. Such purchases must be made within 180 days of the Company’s 3-day volume weighted average stock price being above the exercise price, otherwise, such warrants are void. On December 29, 2020, the Board of Directors adopted, subject to the ratification by the majority shareholders, which ratification occurred pursuant to a majority shareholder consent, effective on December 30, 2020, the Rapid Therapeutic Science Laboratories, Inc. 2020 Equity Incentive Plan. Effective on January 7, 2022, the Board of Directors adopted, subject to the ratification by the majority shareholders, which ratification occurred pursuant to a majority shareholder consent, effective on January 11, 2022, the First Amended and Restated Rapid Therapeutic Science Laboratories, Inc. 2020 Equity Incentive Plan (the “2020 Plan”). The 2020 Plan provides an opportunity for any employee, officer, director or consultant of the Company, subject to limitations provided by federal or state securities laws, to receive (i) incentive stock options (to eligible employees only); (ii) nonqualified stock options; (iii) restricted stock; (iv) stock awards; (v) shares in performance of services; (vi) other stock-based awards; or (vii) any combination of the foregoing. In making such determinations, the Board of Directors may take into account the nature of the services rendered by such person, his or her present and potential contribution to the Company’s success, and such other factors as the Board of Directors in its discretion shall deem relevant. Subject to adjustment in connection with the payment of a stock dividend, a stock split or subdivision or combination of the shares of common stock, or a reorganization or reclassification of the Company’s common stock, the aggregate number of shares of common stock which may be issued pursuant to awards under the 2020 Plan is the sum of (i) 25,000,000 shares, and (ii) an annual increase on March 1st of each calendar year, beginning in 2022 and ending in 2030, in each case subject to the approval of the Board of Directors or the compensation committee of the Company (if any) on or prior to the applicable date, equal to the lesser of (A) five percent (5%) of the total shares of common stock of the Company outstanding on the last day of the immediately preceding fiscal year; (B) 25,000,000 shares of common stock; and (C) such smaller number of shares as determined by the Board of Directors or compensation committee of the of the Company (if any)(the “Share Limit”), also known as an “evergreen” provision. Notwithstanding the foregoing, shares added to the Share Limit are available for issuance as incentive stock options only to the extent that making such shares available for issuance as incentive stock options would not cause any incentive stock option to cease to qualify as such. In the event that the Board of Directors or the compensation committee (if any) does not take action to affirmatively approve an increase in the Share Limit on or prior to the applicable date provided for under the plan, the Share Limit remains at its then current level. Notwithstanding the above, no more than 250,000,000 incentive stock options may be granted pursuant to the terms of the 2020 Plan. The maximum number of shares subject to awards granted during a single calendar year to any non-employee director, taken together with any cash fees paid during the compensation year to the non-employee director, in respect of the director’s service as a member of the Board during such year (including service as a member or chair of any committees of the Board), will not exceed $500,000 in total value (calculating the value of any such awards based on the grant date fair value of such awards for financial reporting purposes). Compensation will count towards this limit for the calendar year in which it was granted or earned, and not later when distributed, in the event it is deferred. Employees, non-employee directors, and consultants of the Company and its subsidiaries are eligible to participate in the 2020 Plan. Incentive stock options may be granted under the 2020 Plan only to employees of the Company and its affiliates. Employees, directors and consultants of the Company and its affiliates are eligible to receive all other types of awards under the 2020 Plan. No awards are issuable by the Company under the 2020 Plan (a) in connection with services associated with the offer or sale of securities in a capital-raising transaction; or (b) where the services directly or indirectly promote or maintain a market for the Company’s securities. The 2020 Plan will automatically terminate on the 10th anniversary of original approval date of the Plan (December 29, 2030). However, prior to that date, the Company’s Board of Directors may amend or terminate the 2020 Plan as it deems advisable, but it cannot adopt an amendment if it would (1) without a grantee’s consent, materially and adversely affect that grantee’s award; or (2) without shareholder approval, increase the number of shares of the Company’s common stock that can be awarded under the 2020 Plan, except as provided for therein. The Company has made no awards under the 2020 Plan to date. In March 2018, the Board approved the establishment of a 2018 Stock Option Plan with an authorization for the issuance of up to 20,000,000 shares of common stock. The Plan is designed to provide for future discretionary grants of stock options, stock awards and stock unit awards to key employees and non-employee directors. The Company has made no awards under the 2018 Stock Option Plan to date.

Related Party Transactions Disc

Related Party Transactions Disclosure	12 Months Ended
	Dec. 31, 2021
Notes
Related Party Transactions Disclosure	(10) Related Party Transactions Office services were provided without charge by our Chief Executive Officer and director, Donal R. Schmidt, Jr., from November 15, 2019 to June 30, 2021 (at which time, the Company relocated to a new leased office location). Such costs are immaterial to the consolidated financial statements and, accordingly, have not been reflected therein. The officers and directors of the Company are involved in other business activities and may, in the future, become involved in other business opportunities. If a specific business opportunity becomes available, such persons may face a conflict in selecting between the Company and their other business interests. The Company’s audit committee is tasked with resolving related party conflicts.

Provision for Income Taxes, Dis

Provision for Income Taxes, Disclosure	12 Months Ended
	Dec. 31, 2021
Notes
Provision for Income Taxes, Disclosure	(11) Provision for Income Taxes The Company accounts for income taxes under FASB Accounting Standard Codification ASC 740 “Income Taxes”. ASC 740 requires use of the liability method. ASC 740 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. Deferred tax assets and liabilities at the end of each period are determined using the currently enacted tax rates applied to taxable income in the periods in which the deferred tax assets and liabilities are expected to be settled or realized. For the year ended December 31, 2021, the Company had net operating loss carry forwards of approximately $2,847,900, after taking certain non-deductible items into account, as compared to $1,694,300 for the nine months ended December 31, 2020. Such net operating loss carry forwards may be available to reduce future years' taxable income, however, any future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined as not likely to occur. Accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards. Net operating losses will begin to expire in 2030. Components of net deferred tax assets, including a valuation allowance, as of December 31, 2021 and 2020, are as follows: December 31, 2021 2020 Deferred tax assets Net operating loss carryforward $ 1,200,100 $ 602,000 Total deferred assets 1,200,100 602,000 Valuation allowance (1,200,100) (602,000) Net deferred tax assets $ - $ - In assessing the recovery of the deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in the periods in which those temporary differences become deductible. Management considers the scheduled reversals of future deferred tax assets, projected future taxable income, and tax planning strategies in making this assessment. As a result, management determined it was more likely than not the deferred tax assets would not be realized as of December 31, 2021. The provision for income taxes differs from the amount computed by applying the statutory federal income tax rate to income before provision for income taxes. The sources and tax effects of the differences are as follows: Year Ended December 31, 2021 Nine Months Ended December 31, 2020 U.S. federal statutory tax rate 21.0% 21.0% Valuation allowance (21.0)% (21.0)% Net effective tax rate 0% 0% At December 31, 2021, we had an unused net operating loss carryover of approximating $5,715,000, after taking certain non-deductible items into account, that is available to offset future taxable income which expires beginning 2038. The availability of such net operating loss carryover to be offset against any future taxable income is significantly limited as a result of a change of control transaction that occurred in November 2019. All prior tax years remain open currently.

Commitments and Contingencies,

Commitments and Contingencies, Disclosure	12 Months Ended
	Dec. 31, 2021
Notes
Commitments and Contingencies, Disclosure	(12) Commitments and Contingencies From time to time in the ordinary course of our business, the Company may be involved in legal proceedings, the outcomes of which may not be determinable. The results of litigation are inherently unpredictable. Any claims against us, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. We are not able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are not probable and estimable, primarily for the following reasons: (i) many of the relevant legal proceedings are in preliminary stages, and until such proceedings develop further, there is often uncertainty regarding the relevant facts and circumstances at issue and potential liability; and (ii) many of these proceedings involve matters of which the outcomes are inherently difficult to predict. We currently have no insurance policies covering such potential losses. We are not at this time involved in any legal proceedings.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Notes
Subsequent Events	(13) Subsequent Events In late January 2022, the Company closed two short-term loans from two different lenders in the total amount of $573,738. One of these loans was from an independent director of the Company in the amount of $400,000. Both of these loans were in the form of unsecured promissory notes bearing interest at a rate of approximately 18% per annum with a maturity of one year. For the larger note from an independent director, the principal amount and accrued interest are due at maturity whereas for the smaller note with an institutional investor, monthly payments of principal and interest are required. In the event of a default by the Company on the payment terms of either note, the notes would be convertible into shares of the Company’s common stock at a conversion price equal to the greater of (a) $0.000075 per share; and (b) 75% of the average closing bid price of the Company’s common stock, on the principal securities exchange or market where the Company’s common stock is then quoted or traded, for the five trading days immediately prior to the date of conversion. The Company expects to use the proceeds of these loans to meet its short-term working capital needs in anticipation of ultimately closing a qualified listing on a national exchange, of which there can be no assurance. On February 11, 2022, the Company made a contingent purchase of lab equipment from the two principals of a private company. Such equipment is ultimately planned to be installed in the Company’s new laboratory and office facility which is currently under construction (see Note 6). The consideration for this purchase consists of: (a) 50,000 shares of Common Stock issued to each of the two principals, and (b) $52,000 in cash payment to be made no later than June 30, 2022, subject to completion of a qualified listing on a national exchange. If such a listing is not completed by that date, the Company may elect to return the equipment, however, the two principals will retain the 100,000 shares as non-cash compensation. On March 8, 2022, the Company fully repaid the note with an institutional investor received in late January 2022 by borrowing funds from a seperate institutional investor, with substantially similar terms, but with a slightly longer maturity in the amount of $197,000. Under this new loan, we are required to make monthly principal and interest payments of $21,276, beginning on May 1, 2022.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies: Basis of Accounting Policy (Policies)	12 Months Ended
	Dec. 31, 2021
Policies
Basis of Accounting Policy	Basis of Accounting -

Summary of Significant Accoun_3

Summary of Significant Accounting Policies: Principles of Consolidation, Policy (Policies)	12 Months Ended
	Dec. 31, 2021
Policies
Principles of Consolidation, Policy	Principles of Consolidation -

Summary of Significant Accoun_4

Summary of Significant Accounting Policies: Cash and Cash Equivalents Policy (Policies)	12 Months Ended
	Dec. 31, 2021
Policies
Cash and Cash Equivalents Policy	Cash and Cash Equivalents -

Summary of Significant Accoun_5

Summary of Significant Accounting Policies: Inventory, Policy (Policies)	12 Months Ended
	Dec. 31, 2021
Policies
Inventory, Policy	Inventory -

Summary of Significant Accoun_6

Summary of Significant Accounting Policies: Property and Equipment, Policy (Policies)	12 Months Ended
	Dec. 31, 2021
Policies
Property and Equipment, Policy	Property and Equipment

Summary of Significant Accoun_7

Summary of Significant Accounting Policies: Intangible Assets, Policy (Policies)	12 Months Ended
	Dec. 31, 2021
Policies
Intangible Assets, Policy	Intangible Assets -

Summary of Significant Accoun_8

Summary of Significant Accounting Policies: Revenue Recognition, Policy (Policies)	12 Months Ended
	Dec. 31, 2021
Policies
Revenue Recognition, Policy	Revenue recognition FASB ASU Revenue from Contracts with Customers (Topic 606).

Summary of Significant Accoun_9

Summary of Significant Accounting Policies: Earnings per share, Policy (Policies)	12 Months Ended
	Dec. 31, 2021
Policies
Earnings per share, Policy	Earnings per Share -

Summary of Significant Accou_10

Summary of Significant Accounting Policies: Income Taxes, Policy (Policies)	12 Months Ended
	Dec. 31, 2021
Policies
Income Taxes, Policy	Income Taxes -

Summary of Significant Accou_11

Summary of Significant Accounting Policies: Use of Estimates, Policy (Policies)	12 Months Ended
	Dec. 31, 2021
Policies
Use of Estimates, Policy	Use of Estimates - Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from estimates.

Summary of Significant Accou_12

Summary of Significant Accounting Policies: Fair value of financial instruments, Policy (Policies)	12 Months Ended
	Dec. 31, 2021
Policies
Fair value of financial instruments, Policy	Fair Value of Financial Instruments - Level 1: The preferred inputs to valuation efforts are “ quoted prices in active markets for identical assets or liabilities, Level 2: FASB acknowledged that active markets for identical assets and liabilities are relatively uncommon and, even when they do exist, they may be too thin to provide reliable information. To deal with this shortage of direct data, the board provided a second level of inputs that can be applied in three situations. Level 3: If inputs from levels 1 and 2 are not available, FASB acknowledges that fair value measures of many assets and liabilities are less precise. The board describes Level 3 inputs as “ unobservable,

Summary of Significant Accou_13

Summary of Significant Accounting Policies: Recently Issued Accounting Pronouncements (Policies)	12 Months Ended
	Dec. 31, 2021
Policies
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements

Summary of Significant Accou_14

Summary of Significant Accounting Policies: Subsequent Events, Policy (Policies)	12 Months Ended
	Dec. 31, 2021
Policies
Subsequent Events, Policy	Subsequent Events

Property and Equipment Disclo_2

Property and Equipment Disclosure: Schedule of Property and Equipment Balances (Tables)	12 Months Ended
	Dec. 31, 2021
Tables/Schedules
Schedule of Property and Equipment Balances	December 31, 2021 2020 Equipment purchased from Razor Jacket, LLC and awaiting installation in the Company's new facilities in Addison, Texas $ 500,000 $ 500,000 Equipment located in the Company's existing facilities in Addison, Texas 221,412 104,240 Leasehold improvements in progress at the Company's new facilities in Addison, Texas 491,005 - Leasehold improvements in the Company's existing facilities in Addison, Texas 2,500 2,500 Total property and equipment 1,214,917 606,740 Less: Accumulated depreciation (29,355) (7,255) Net property and equipment $ 1,185,562 $ 599,485

Notes Payable Disclosure_ Sched

Notes Payable Disclosure: Schedule of long-term debt obligations (Tables)	12 Months Ended
	Dec. 31, 2021
Tables/Schedules
Schedule of long-term debt obligations	December 31, 2021 2020 Convertible debenture issued to an accredited investor on August 4, 2021, due May 1, 2022 in principal amount of $1,941,176, original issue discount of 15%, convertible at option of investor into a total of 4,852,940 shares of common stock at $0.40 per share and automatically convertible at 25% discount to the price per share of common stock in a qualified offering (net of unamortized debt discount of $866,128 as of December 31, 2021) $ 1,075,048 $ - Promissory note issued to an accredited investor on November 10, 2020, accruing interest at 5% per annum, due on January 10, 2021, along with lending fee of 20,000 shares of common stock - 300,000 Convertible promissory notes issued to two accredited investors on November 15, 2019, maturing in 1 to 5 years, accruing interest at 5% per annum, convertible into common stock at $0.05 per share 150,000 150,000 Unsecured advances received from two officers in May through August 2021, accruing interest at 1% per annum, payable on demand 260,000 - - Convertible promissory notes issued to former owners in acquisition of Power Blockchain, accruing interest at 5% per annum, principal repayments originally due in four equal installments on 2nd, 3rd, 4th and 5th anniversaries, convertible into common stock at $0.13 per share, with final maturity on February 1, 2023. - 165,240 Other short term notes issued to various affiliates of the former owners of Power Blockchain for acquisition of Treasury Stock, computers and equipment, and working capital financing, at stated interest rates of 10%. Amended on November 15, 2019, to mature in one year and to be convertible into common stock at $0.05 per share. 48,386 351,933 Convertible notes issued to an accredited investor in three tranches from June to August 2020, net of unamortized debt discount of $43,306 (see further discussion below) - 46,694 Total notes payable $ 1,533,434 $ 1,013,867

Notes Payable Disclosure_ Futur

Notes Payable Disclosure: Future maturities of notes payable (Tables)	12 Months Ended
	Dec. 31, 2021
Tables/Schedules
Future maturities of notes payable	Year ending December 31, 2022 $ 2,249,562 Year ending December 31, 2023 - Year ending December 31, 2024 150,000 $ 2,399,562

Long Term Lease Obligation Di_2

Long Term Lease Obligation Disclosure: Future operating lease minimum payments (Tables)	12 Months Ended
	Dec. 31, 2021
Tables/Schedules
Future operating lease minimum payments	Year ending December 31, 2022 $ 94,226 Year ending December 31, 2023 98,509 Year ending December 31, 2024 102,792 Year ending December 31, 2025 107,075 Year ending December 31, 2026 111,358 Total future minimum lease payments 513,960 Less amounts representing interest (61,927) Present value of lease liability 452,033 Current portion of operating lease liability (73,289) Long-term portion of operating lease liability $ 378,744

Provision for Income Taxes, D_2

Provision for Income Taxes, Disclosure: Components of net deferred tax assets, including a valuation allowance (Tables)	12 Months Ended
	Dec. 31, 2021
Tables/Schedules
Components of net deferred tax assets, including a valuation allowance	December 31, 2021 2020 Deferred tax assets Net operating loss carryforward $ 1,200,100 $ 602,000 Total deferred assets 1,200,100 602,000 Valuation allowance (1,200,100) (602,000) Net deferred tax assets $ - $ -

Provision for Income Taxes, D_3

Provision for Income Taxes, Disclosure: Sources and tax effects of the differences (Tables)	12 Months Ended
	Dec. 31, 2021
Tables/Schedules
Sources and tax effects of the differences	Year Ended December 31, 2021 Nine Months Ended December 31, 2020 U.S. federal statutory tax rate 21.0% 21.0% Valuation allowance (21.0)% (21.0)% Net effective tax rate 0% 0%

Going Concern Disclosure (Detai

Going Concern Disclosure (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Details
Accumulated deficit	$ 8,521,423	$ 5,653,540

Intangible Assets Disclosure (D

Intangible Assets Disclosure (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Additions to property and equipment	$ 292,531	$ 106,740
Sublicense agreement with Texas MDI
Stock issued in acquisition of assets, shares			140,000,000
Stock issued in acquisition of assets, value			$ 140,000
Additions to property and equipment			$ 135,000
Accrued liabilities, net		$ 44,925
Sublicense agreement, gross	$ 170,075

Asset Acquisition Disclosure (D

Asset Acquisition Disclosure (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
General and administrative	$ 2,114,770	$ 2,023,379
Asset Purchase and Sales Agreement with Razor Jacket, Cash Paid
General and administrative		$ 300,000
Asset Purchase and Sales Agreement with Razor Jacket, Stock Issued
Stock issued in acquisition of assets, shares		625,000
Asset Purchase and Sales Agreement with Razor Jacket, Stock Value
Stock issued, non-cash		$ 500,000

Property and Equipment Disclo_3

Property and Equipment Disclosure: Schedule of Property and Equipment Balances (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Property and equipment, gross	$ 1,214,917	$ 606,740
Accumulated depreciation	(29,355)	(7,255)
Net property and equipment	1,185,562	599,485
Equipment purchased from Razor Jacket
Property and equipment, gross	500,000	500,000
Equipment located in the Company's facilities
Property and equipment, gross	221,412	104,240
Leasehold improvements in progress at new facilities
Property and equipment, gross	491,005	0
Leasehold improvements in the Company's facilities
Property and equipment, gross	$ 2,500	$ 2,500

Property and Equipment Disclo_4

Property and Equipment Disclosure (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Accounts payableand accrued liabilities, net	$ 465,204	$ 112,298
Commercial lease at new facilities
Accounts payableand accrued liabilities, net	$ 315,646

Notes Payable Disclosure_ Sch_2

Notes Payable Disclosure: Schedule of long-term debt obligations (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Convertible debt payable	$ 1,533,434	$ 1,013,867
Convertible debenture issued to an accredited investor, Aug 4 2021
Convertible debt payable	1,075,048
Promissory note issued to an accredited investor, Nov 10 2020
Convertible debt payable		300,000
Convertible promissory notes issued to two accredited investors, Nov 15 2019
Convertible debt payable	150,000	150,000
Unsecured advances received from two officers
Convertible debt payable	260,000
Convertible promissory notes issued to former owners
Convertible debt payable		165,240
Other short term notes issued to various affiliates
Convertible debt payable	$ 48,386	351,933
Convertible notes issued to an accredited investor, June to Aug 2020
Convertible debt payable		$ 46,694

Notes Payable Disclosure (Detai

Notes Payable Disclosure (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Proceeds from Issuance of convertible debenture payable	$ 1,650,000	$ 0
Amortization of debt discount	1,147,865	0
Warrant liability and other derivatives	1,085,360	43,306
Gain (loss) on valuation of warrant liability	631,853	0
Proceeds from notes payable - related party	260,000	0
Stock issued for conversion of debt, value	890,031	$ 535,074	$ 2,034,760
Stock issued for accrued interest and lending fees, value	2,292
Stock issued for conversion of debt, shares			15,652,000
Convertible debenture issued to an accredited investor, Aug 4 2021
Proceeds from Issuance of convertible debenture payable	1,650,000
Amortization of debt discount	$ 161,764
Conversion price per share	$ 0.40
Warrants issued with convertible debt	4,852,940
Convertible debenture Placement Agent
Conversion price per share	$ 0.40
Warrants issued with convertible debt	242,647
Convertible debenture Warrants issued
Amortization of debt discount	$ 980,497
Warrant liability and other derivatives	1,085,360
Gain (loss) on valuation of warrant liability	$ 631,853
Various notes in 2018 and 2019
Conversion price per share		$ 0.05
Stock issued for conversion of debt, value		$ 404,601
Stock issued for accrued interest and lending fees, value		$ 96,536
Stock issued for conversion of debt, shares		10,022,749
Convertible notes 2018 at $0.13
Conversion price per share	$ 0.13
Stock issued for conversion of debt, value	$ 410,888
Stock issued for conversion of debt, shares	3,160,684
Convertible notes 2019 at $0.05
Conversion price per share	$ 0.05
Stock issued for conversion of debt, value	$ 383,470
Stock issued for conversion of debt, shares	7,669,381
Securities Purchase Agreements Notes
Stock issued for conversion of debt, value		$ 35,000
Stock issued for conversion of debt, shares	264,520	80,775
Promissory notes with two accredited investors
Proceeds from notes payable - related party			$ 300,000

Long Term Lease Obligation Di_3

Long Term Lease Obligation Disclosure: Future operating lease minimum payments (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Details
Due December 31, 2022	$ 94,226
Due December 31, 2023	98,509
Due December 31, 2024	102,792
Due December 31, 2025	107,075
Due December 31, 2026	111,358
Current portion of operating lease obligation	73,289	$ 0
Long-term portion of operating lease obligation	$ 378,744	$ 0

Long Term Lease Obligation Di_4

Long Term Lease Obligation Disclosure (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Details
Operating lease right-of-use asset, net	$ 425,171	$ 0
Operating lease obligation total	452,033
Long-term portion of operating lease obligation	$ 378,744	$ 0

Stockholders' Equity Disclosu_2

Stockholders' Equity Disclosure (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Common Stock, Shares Authorized	750,000,000	750,000,000
Stock issued for conversion of debt, value	$ 890,031	$ 535,074	$ 2,034,760
Stock issued for accrued interest and lending fees, value	2,292
Stock issued for conversion of debt, shares			15,652,000
Private offering of common stock, value	$ 585,000	$ 2,012,500
private stock subscription agreements with various accredited investors
Private offering of common stock, shares	1,462,500
Price per share sold	$ 0.40
Private offering of common stock, value	$ 585,000
2020 Equity Incentive Plan
Common stock authorized under Stock Option Plan	250,000,000
2018 Stock Option Plan
Common stock authorized under Stock Option Plan	20,000,000
Various notes in 2018 and 2019
Conversion price per share		$ 0.05
Stock issued for conversion of debt, value		$ 404,601
Stock issued for accrued interest and lending fees, value		$ 96,536
Stock issued for conversion of debt, shares		10,022,749
Convertible notes 2018 at $0.13
Conversion price per share	$ 0.13
Stock issued for conversion of debt, value	$ 410,888
Stock issued for conversion of debt, shares	3,160,684
Convertible notes 2019 at $0.05
Conversion price per share	$ 0.05
Stock issued for conversion of debt, value	$ 383,470
Stock issued for conversion of debt, shares	7,669,381
Series A Preferred Stock
Preferred Stock, Shares Authorized	16,500,000
Series B Preferred Stock
Preferred Stock, Shares Authorized	2,000,000
Series C Preferred Stock
Preferred Stock, Shares Authorized	8,500,000

Provision for Income Taxes, D_4

Provision for Income Taxes, Disclosure (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Details
Net operating loss carry forwards	$ 2,847,900	$ 1,694,300

Provision for Income Taxes, D_5

Provision for Income Taxes, Disclosure: Components of net deferred tax assets, including a valuation allowance (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Details
Net operating loss carry forward for deferred tax assets	$ 1,200,100	$ 602,000
Total deferred assets	1,200,100	602,000
Valuation allowance	(1,200,100)	(602,000)
Net deferred tax assets	$ 0	$ 0

Provision for Income Taxes, D_6

Provision for Income Taxes, Disclosure: Sources and tax effects of the differences (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Details
U.S. federal statutory tax rate	21.00%	21.00%
Valuation allowance, percentage	(21.00%)	(21.00%)
Net effective tax rate	0.00%	0.00%

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	1 Months Ended	2 Months Ended	12 Months Ended
	Jan. 31, 2022	Mar. 08, 2022	Dec. 31, 2021	Dec. 31, 2020
Proceeds from notes payable - related party			$ 260,000	$ 0
Proceeds from notes payable - other			$ 0	$ 422,000
Short term promissory note
Proceeds from notes payable - related party	$ 573,738
New loan from institutional investor
Proceeds from notes payable - other		$ 197,000